Have you or your loved ones been diagnosed with uveal melanoma?

You may be eligible to participate in a uveal melanoma clinical trial.

Have you or your loved ones been diagnosed with uveal melanoma? You may be eligible to participate in a uveal melanoma clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Uveal Melanoma Clinical Trial in Vienna

NCT00872391 | Interventional

Have you or your loved ones been diagnosed with uveal melanoma?

You may be eligible to participate in a uveal melanoma clinical trial.

Have you or your loved ones been diagnosed with uveal melanoma? You may be eligible to participate in a uveal melanoma clinical trial.

Recruiting

Male & Female

18 Years +

This study is looking to recruit 155 Participants

The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target volume (PTV) in patients with uveal melanoma. Patients will be followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity, secondary complications and survival.

Show me more details

Details for the study

Brief Title

Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma

Official Title

Safety and Efficacy of Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Malignant Melanoma of the Uvea

Brief Summary

The purpose of this study is to assess the safety and efficacy of hypofractionated<br /> stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for<br /> the planning target volume (PTV) in patients with uveal melanoma. Patients will be<br /> followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity,<br /> secondary complications and survival.

Treatments and/or Procedures

Hypofractionated linear accelerator radiotherapy

10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.

Study Criteria

Inclusion Criteria:

  -  The initial height of the melanoma is 7 mm or higher.

  -  Juxtapapillary and/or juxtamacular melanomas with a height of 3 mm or higher and if
     the central tumor distance to the optic disc and/or the macula is 3 mm or less.

  -  If other forms of conservative treatment of the melanoma are not possible.

Exclusion Criteria:

  -  Prior/Concomitant Treatment.

  -  Extrascleral tumor extension is present.

  -  If the presence of neovascular glaucoma is detected before treatment.

  -  If metastasis is detected at baseline.

  -  Previous participation in any study of investigational drugs within 3 month preceding
     day 0.

  -  Pregnant women are not allowed to participate in the study.